Annexin Pharmaceuticals AB Working Capital to Net Assets Ratio
Annexin Pharmaceuticals AB working capital to net assets ratio. Annexin Pharmaceuticals AB (ANNX) has a Working Capital to Net Assets ratio of 89.3% as of March 2026. Working capital of Skr12.87 Million (current assets of Skr18.43 Million minus current liabilities of Skr5.56 Million) is measured against net assets of Skr14.42 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check how tangible is Annexin Pharmaceuticals AB's equity to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Annexin Pharmaceuticals AB (2014–2025)
Working capital to net assets ratio of Annexin Pharmaceuticals AB from 2014 to 2025. This chart shows how Annexin Pharmaceuticals AB's Working Capital to Net Assets ratio has evolved across 12 annual periods from 2014 to 2025. As of March 2026, the ratio stands at 89.3%, reflecting working capital of Skr12.87 Million against net assets of Skr14.42 Million SEK. See ANNX defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annexin Pharmaceuticals AB Working Capital to Net Assets Ratio by Year (2014–2025)
Annexin Pharmaceuticals AB working capital to net assets ratio by year from 2014 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Annexin Pharmaceuticals AB from 2014 to 2025, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see total assets of Annexin Pharmaceuticals AB.
| Year | WC/NA Ratio | Working Capital (SEK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 93.6% | Skr23.34 Million | Skr24.93 Million | Skr28.57 Million | Skr5.22 Million | ▲ +5.7 pp |
| 2024 | 87.9% | Skr12.06 Million | Skr13.71 Million | Skr17.38 Million | Skr5.32 Million | ▼ -2.2 pp |
| 2023 | 90.2% | Skr16.97 Million | Skr18.81 Million | Skr24.91 Million | Skr7.95 Million | ▲ +0.2 pp |
| 2022 | 90.0% | Skr27.12 Million | Skr30.15 Million | Skr33.65 Million | Skr6.53 Million | ▼ -5.6 pp |
| 2021 | 95.6% | Skr44.66 Million | Skr46.73 Million | Skr50.72 Million | Skr6.06 Million | ▲ +6.5 pp |
| 2020 | 89.0% | Skr18.38 Million | Skr20.64 Million | Skr22.90 Million | Skr4.52 Million | ▲ +9.6 pp |
| 2019 | 79.5% | Skr9.13 Million | Skr11.49 Million | Skr13.68 Million | Skr4.55 Million | ▼ -14.7 pp |
| 2018 | 94.2% | Skr37.53 Million | Skr39.85 Million | Skr43.49 Million | Skr5.96 Million | ▲ +3.2 pp |
| 2017 | 90.9% | Skr22.23 Million | Skr24.44 Million | Skr28.16 Million | Skr5.93 Million | ▼ -4.9 pp |
| 2016 | 95.8% | Skr14.93 Million | Skr15.57 Million | Skr22.08 Million | Skr7.16 Million | ▲ +687.8 pp |
| 2015 | -592.0% | Skr811.00K | Skr-137.00K | Skr1.69 Million | Skr883.00K | ▼ -656.6 pp |
| 2014 | 64.6% | Skr1.75 Million | Skr2.71 Million | Skr2.03 Million | Skr281.14K | — |